Individualizing and Optimizing Asthma Care. CFW 2018 Friday, April 13, 9:45 11:15 am Renaissance Austin Hotel in Austin, Texas
|
|
- Joy Marshall
- 5 years ago
- Views:
Transcription
1 Individualizing and Optimizing Asthma Care CFW 2018 Friday, April 13, 9:45 11:15 am Renaissance Austin Hotel in Austin, Texas
2 Speaker Disclosure Dr. Hawkins has disclosed that he has no actual or potential conflict of interest in relation to this topic.
3 Objectives By completing this educational activity, the participant should be better able to: 1. Discuss the components of pulmonary function tests, indications, and interpretation of spirometry. 2. Accurately diagnose asthma and be able to differentiate the appropriate disease severity classification for each patient. 3. Appreciate the role of various medical therapies in the management of asthma and demonstrate the ability to adjust therapy as indicated to attain the best disease control in the asthma patient. 4. Provide patients practical tools for self management.
4 Children with Asthma Self limited wheezing illness in early childhood Some persist through adulthood Difficult to diagnose under age 6 Improvement: 12 month exacerbations declined from about 62 percent in 2001 to about 54 percent in Vital Signs: Asthma in Children United States, MMWR Weekly / February 9, 2018 / 67(5);
5 # 1. Pulmonary Function Testing SPIROMETRY Objective Measurement of Lung Function Pulmonary function tests Indications for Spirometry Diagnosis of airflow limitation Severity of Obstruction Response to Therapy Goal is to give enough medications to achieve normal lung function
6 ARS Question 1 1. I do not have an office Spirometer. 2. I have one but do not feel confident using it. 3. I have one and feel confident but don t have time/workflow. 4. I have one, I feel confident, but don t use it and feel guilty.
7 Coding and Reimbursement Procedure CPT Code Reimbursement* Single Spirometry $32.82 Pre post Spirometry $57.71 Pulmonary stress test simple $71.77 Medication administration bronchodilator supply separate $13.34 Demonstration / instruction $14.79 Smoking Cessation <8x/ yr $12.98 Equipment Cost Office Spirometer $1,500 2,500
8 Coding and Reimbursement Tests /week (#) Reimbursement/year* ROI $1,995 in weeks 4 $6, $10, $13, $17, $25, $34, $42,900 2 *Based upon CPT code ESTIMATED RETURN ON INVESTMENT
9 Coding and Reimbursement Diagnosis Code Cough (smokers) J41.0 Simple chronic bronchitis J42 Mucopurulent chronic bronchitis J41.1 Acute bronchitis J20.9 Chronic obstructive pulmonary J44.9 disease Shortness of breath R06.02 Restrictive lung disease (other diseases.) Asthma J45
10 Three Numbers FVC: Forced Vital Capacity FEV1: Amount breathed out in 1 second FEV1/FVC: How much of your lung s air can be exhaled in the first second Measure of caliber or function of airway NOT A COMPARISON TO REFERENCE VALUES More accurate than Peak Flow
11 Lung Volumes ERV + RV = Functional Residual Capacity Inspiratory Capacity Vital Capacity Tidal Volume Expiratory Reserve Volume Residual Volume
12 OBSTRUCTION? FEV1/FVC 70 Overestimates COPD diagnosis in elderly Underestimates COPD diagnosis in those under age 45
13 Severity of Obstruction FEV1 % of predicted Mild >80 Moderate 50 to 79 Severe 30 to 49 Very severe <30 * Severity of Restriction FVC % of predicted Mild >65 to 80 Moderate >50 to 64 Severe <50
14 FEV1 Thresholds Grade 1: Mild FEV1 > 80% Grade 2: Moderate 50% < FEV1 < 80% Grade 3: Severe 30% < FEV1 < 50% Grade 4: Very Severe FEV1 < 30%
15 Normal Flow Volume Curve (Expiratory) PEFR 8 Flow (L/sec) 6 4 FEV Volume (L)
16 Normal, Obstructed, & Restrictive Curves Normal Obstruction Restriction Flow (L/sec) Volume (L)
17 Maximal Forced Expiratory Maneuver Public Health Image Library, (PHIL), #20950, Veronica Burkel, M.P.H., 2013, accessed 8/11/16, public domain
18 Public Health Image Library, (PHIL), # 19298, Daniel A. Singer, MD, MPH, Medical Officer accessed 8/11/16, public domain Coaching Blow, Blow, Blow!
19 Inspiratory Volume Loop Expiratory Flattened Inspiratory Loop Indicating possible Extrathoracic Obstruction
20 Is FEV 1 / FVC Ratio Low? (<70%) Yes Obstructive Defect Is FVC Low? (<80% pred) Yes Combined Defect of Obstruction and Restriction /or Hyperinflation No Pure Obstruction Reversible Obstruction with ß agonist Reversible Obstruction and improved FVC with ß agonist Adapted with permission from J S Lowry No Further Testing with Full PFT s Yes Yes Suspect Asthma No Suspect COPD
21 Common Obstructive Disorders Diffuse Airway Disease Asthma COPD Bronchiectasis Cystic Fibrosis Upper Airway Obstruction Foreign Body Neoplasm Tracheal Stenosis Tracheomalacia Vocal Cord Paralysis
22 Is FEV 1 / FVC Ratio Low? (<70%) Diagnostic Flow Diagram, Restriction No Is FVC Low? (<80% pred) Yes No Restrictive Defect Normal Spirometry Further Testing with Full PFT s and consider referral
23 Common Restrictive Disorders Parenchymal Interstitial Lung Diseases Fibrosis Granulomatosis (TB) Pneumoconiosis Pneumonitis (lupus) Loss of Functioning Tissue Atelectasis Large Neoplasm Resection Pleural Effusion Fibrosis Chest Wall Kyphoscoliosis Neuromuscular Disease Trauma Extrathoracic Abdominal Distension Obesity
24 Asthma or COPD? Underlying immune mechanism of chronic inflammation different Age of onset Earlier in life with asthma Usually > age 40 in COPD Symptoms in asthma vary; COPD slowly progressive Smoking associated with COPD Asthma with reversible airflow limitation; irreversible airflow limitation in COPD Allergic Symptoms with Asthma
25 Case # 1: Rachel 58 yo Woman Previous visits for acute bronchitis treated with antibiotics Half a pack/day for 20 years (10 pk. Yrs.) Grew up in family of smokers Worsening x 3 months Complains of SOB when walking up stairs Wheezing waking her at night and productive cough
26 Case #1: Rachel Spirometry Results Flow (L/sec) Age: 58 Height: 160 cm Sex: Female Ethnicity: Caucasian Pre bronchodilator Post bronchodilator Volume (L) 6
27 Case #1: Rachel Spirometry Results Pre Bronchodilator Post Bronchodilator Predicted Measured % Predicted Measured % Change FVC 4.37 L 4.65 L 106% 4.65 L 0% FEV L 2.98 L 79% 3.19 L 7% FEV 1/ FVC (%) 86% 64% 69% Office Staff eager to leave at end of day and only waited 5 minutes before tests
28 Case #1: Rachel Spirometry Results Pre Bronchodilator Post Bronchodilator Predicted Measured % Predicted Measured % Change FVC 4.37 L 4.65 L 106% 4.65 L 0% FEV L 2.98 L 79% 3.50 L 17.5% FEV 1/ FVC (%) 86% 64% 75% After waiting the full 20 minutes.
29 ARS Question 2 Case #1: Rachel Diagnosis 1. Mild Intermittent Asthma 2. Reversible Airways Disease 3. Mild Persistent Asthma 4. Mild COPD
30 Spirometry Technique Forced expiratory maneuver Coach patient to get a maximal effort Six seconds of effort required though most of air pushed out in the first second Pace of expired air is most important variable; therefore it should be released with explosive force 4 MDI of 100 ug Albuterol preferably with a spacer Wait 20 minutes for full effect
31 CASE #2: Julie History 39 year old woman Smoker ++Extrinsic allergies SOBOE with white sputum x 1 week (Technique?)
32 CASE #2: JULIE More HISTORY 3 visits to the ER in previous 2 days No previous measure of airflow (i.e. PEFR or Spirometry) Treated with Antibiotics Little improvement Family history is positive for asthma
33 CASE #2: JULIE SPIROMETRY RESULTS Pre Post Flow (L/sec) Volume (L)
34 Case #2: Julie Simplified Spirometry Pre Bronchodilator Post Bronchodilator Measured % Measured % % change FVC FEV FEV1/ FVC 63% = 400 cc improvement
35 Definition of Reversibility Pre Bronchodilator Post Bronchodilator FEV 1 / FVC below 70% 12% and at least 200cc Reversibility = Asthma!
36 ARS Question 3 Case #2: Julie What is her diagnosis? 1. Mild Intermittent Asthma 2. Mild Persistent Asthma 3. Moderate Persistent Asthma 4. Severe Persistent Asthma 5. Mild COPD
37 Case #2: Julie Explanation Although she is a smoker she changes after bronchodilator by 36% and 400 cc, therefore she has reversible airways disease or ASTHMA She needs Anti inflammatory therapy After bronchodilation she has a persisting obstruction and restriction so we would need to reassess her after three months of asthma therapy. Moderate persistent asthma because FEV is <80% of predicted
38 Case #2: Julie Explanation (Restriction) Restriction due to Air Trapping Lungs are full and can t take any more Not enough air getting in or out Could be from lungs too full? Air Trapping Could be from lungs not getting full enough? Chest wall, or pleural restriction?
39 Measurement Thresholds Severity of Obstruction FEV1 % of predicted Mild >80 Moderate 50 to 79 Severe 30 to 49 Very severe <30 * Severity of Restriction FVC % of predicted Mild >65 to 80 Moderate >50 to 64 Severe <50
40 2. Asthma Diagnosis and Stratification, (Severity) Separate patients with minor illness from major illness Appropriately deploy medications Prevent Ambulatory Sensitive Hospitalizations
41 Rule of 2s Is the Asthma Persistent? Is there Ongoing Inflammation? Take a quick relief (rescue) inhaler (like albuterol) for problems more than 2 times a week Awaken at night with asthma problems more than 2 times a month Refill a quick relief inhaler more than 2 times a year Persistent Asthma: Therefore need a controller medication
42 NHLBI Disease Severity Mild Intermittent Asthma (ICD 10 = J45.20) No air flow limitation between episodes of asthma Low risk Low functional limitation Persistent Asthma (ongoing inflammation) Mild Persistent Moderate Persistent Severe Persistent
43 NHLBI: table 2.2 accessed March 10, 2018
44 Limitations to Grading Severity Four grades split at 80%, 50% and 30% of predicted value Measuring Airway function doesn t always predict disease trajectory (prognosis)? Therefore Combine with Dyspnea & Exacerbation Frequency to choose treatment regimen
45
46
47 3. Therapy: NHLBI Stepped Care Mild Persistent Moderate Persistent Severe Persistent
48 Medication Types ICS Inhaled Corticosteroid SABA Short Acting Beta Agonist LABA Long Acting Beta Agonist SAMA Short Acting Anti muscarinic (Anticholinergic) LAMA Long Acting Anti muscarinic LTRA Leukotriene Receptor Antagonist Monoclonal Antibody Omalizumab
49 MDI (Metered Dose Inhalers) Small and large particles of medication delivered by a propellant, formerly CFC, then HFA since 2007 Improved delivery with spacer to remove large particles Avoids 20 min of nebulization and especially B agonist side effects: anxiety, tremor Covered by Medicare D (Medicare B covers nebulizers)
50 Spacer = Nebulizer with Less S/E
51 Dry Powder Inhalers Smaller Particles More distal delivery in tracheo bronchial tree Less excess medication in GI tract Therefore less side effects However some patients feel they don t get the Kick that they feel from a SABA Need encouragement and coaching Need to know about daily use not prn
52 Long Acting Beta Agonists (LABA) SERAVENT Diskus, (salmeterol) DPI device (FDA approved for Asthma > 4y and EIB) FORADIL Aerolizer, (formoterol) (FDA approved for Asthma > 5 y as add on to longterm control med) BROVANA, arformoteral neb (not FDA approved for Asthma) PERFORMIST, (salmeterol) Neb (Not FDA approved for Asthma) STRIVERDI Respimat, (olodaterol) DPI device (not FDA approved for Asthma) ARCAPTA Neohaler, (indacaterol) (not FDA approved for Asthma) Fanta C, Drug Therapy: Asthma N Engl J Med 2009;360:
53 Inhaled Corticosteroid, ICS FLOVENT MDI or Diskus (44, 110, 220 fluticasone) DPI Device (FDA approved >4 y asthma) QVAR MDI (40 & 80 beclomethasone) HFA MDI (FDA Asthma > 4y asthma) ASMANEX Twisthaler ( y, 220 >12y) (FDA approved > 4 y, asthma) PULMICORT Tubohaler, (200 budesonide) (DPI Device) (FDA 6 y asthma) PULMICORT Flexhaler, (90 & 180 budesonide) DPI Device FDA > 6) PULMICORT Respules (budesonide) Neb bid (FDA > 6) AEROSPAN Aerosol, (80 & 160 flunisolide) HFA MDI (FDA > 6 y) ALVESCO Aerosol, (80 & 160 ciclesonide) HFA MDI (FDA approved >12 y asthma) ASMANEX HFA MDI, (100 & 200 mometasone) DPI (FDA approved > 12 y Asthma) ARNUITY Ellipta, (100 & 200 fluticasone) DPI device FDA >12
54 Combo LABA & ICS ADVAIR Diskus, salmeterol & fluticasone, 250/50, (125/50, 500/ 50) (45/21 115/21 230/21 bid MDI) FDA approved 2000 Asthma >12y) SYMBICORT, formoterol & budesonide) (80/45, 160/45 (FDA approved for Asthma >12) BREO Ellipta, daily (vilanterol & fluticasone) (FDA approved in Asthma > 18y) DULERA Aerosol, (100/5 and 200/5 ii bid (formoterol & mometasone) (FDA >12 y 2010)
55 Anticholinergic LAMA SPIRIVA Handihaler or Respimat, tiotropium DPI (FDA approved Respimat 1.25 mcg for uncontrolled asthma in patients aged 6 years on ICS or ICS + LABA) not 2.5 Respimat INCRUSE Ellipta, (umeclidinium) DPI (Not FDA approved for Asthma) SEEBRI Neohaler, (glycopyrrolate) DPI (Not FDA approved for Asthma)
56 LAMA & LABA NOT approved for Asthma by FDA ANORO Ellipta (umeclidinium & vilanterol) (not FDA approved for Asthma) STIOLTO Respimat (tiotropium & olodaterol) (Not FDA approved for Asthma) UTIBRON Neohaler (glycopyrrolate & indacaterol) (Not FDA approved for Asthma) BEVESPI Aerosphere (formoterol & glycopyrrolate) Not FDI approved for asthma)
57 ICS, LAMA, LABA? Trelegy: Fluticasone, Umeclidinium, vilanterol Not FDA approved for Asthma
58 4. Self Management Tools Peak Flow Meters Good to dx or refute asthma with exercise Good to diagnose occupational Asthma Good to monitor response Asthma Action Plan
59 Exercise Induced Bronchospasm (EIB) This is not asthma ICS don t help Must be differentiated from Exercise worsening moderate persistent asthma SABA or LAMA Salmeterol or Formoterol no more than twice daily
60 Occupational Asthma High Molecular Weight Sensitization (>10kD) Protein or glycopeptide, usually with rhinosinusitis symptoms Animals, cereals & grains, fungi, plant products (latex) Low Molecular Weight Sensitization Diisocyanetes (polyurethane foams etc.) Wood dusts, platinum salts, phenol formaldehyde, antibiotic inhalation (pharmacists) Irritant Exposure (i.e. 9/11 World Trade Center) alkaline dust New onset after high level exposure (16% of those exposed, and after 9 y only 40% of those recovered) Tarlo & Lemiere Occupational Asthma NEJM 370(7) Feb 13, 2014
61 Peak Flow Meter Encourages self awareness Concept of Personal Best Also helpful to diagnose E.I.B and Occupational Asthma
62 NHLBI Asthma Action Plan
63 Zones Green Zone (more than L/min [80 percent of your personal best number]) good control. Yellow Zone (between L/min and L/min [50 to less than 80 percent of your personal best number]) caution take an inhaled SABA. Increase daily medicines. Red Zone (below L/min [less than 50 percent of your personal best number]) signals a medical alert. Inhaled SABA (quick relief medicine) right away. Urgent medical attention, for treatment of exacerbation or step up care
64 Environment: Dust Mites Encase your mattress & Pillow in a special dust mite proof cover. Or wash the pillow each week in hot water. Water must be hotter than 130 F to kill the mites. (Cooler water used with detergent and bleach can also be effective.) Wash the sheets and blankets on your bed each week in hot water.
65 Other Strategies Which Mite Help Reduce indoor humidity to or below 60 percent; ideally percent. Dehumidifiers or central air conditioners can do this. Try not to sleep or lie on cloth covered cushions or furniture. Remove carpets from your bedroom and those laid on concrete Keep stuffed toys out of the bed, or wash the toys weekly in hot water or in cooler water with detergent and bleach. Placing toys weekly in a dryer or freezer may help. Prolonged exposure to dry heat or freezing can kill mites but does not remove allergen.
66 Other Self care Particle Awareness in Atmosphere Ozone Index Influenza vaccination Pneumococcal vaccination Smoking Cessation
67 Readiness to Quit Caring Messages at every visit Evidence shows FPs are effective It takes 6 attempts for many people, don t give up
68 Smoking Cessation Ask, Advise, Assess, Assist, Arrange Only intervention to affect natural history Pharmacological Nicotine Replacement E cigarettes?, not likely an effective substitute Bupropion Varenicline
69 Summary Diagnose Wheezing illness by symptoms < 6 y Diagnose using Spirometry and goal is to achieve normal lung function (evaluate q 3 m) Intervene with Environmental Factors Vaccinate with Influenza & PCV 23 >19y Smoking Cessation and avoid ETS
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationMANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationCOPD A Breath of Fresh Air. Clare Hawkins, MD, FAAFP SW Regional Medical Officer Aspire Healthcare/Anthem
COPD A Breath of Fresh Air Clare Hawkins, MD, FAAFP SW Regional Medical Officer Aspire Healthcare/Anthem Speaker Disclosure Dr. Hawkins has disclosed that he has no actual or potential conflict of interest
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationFASENRA (benralizumab)
FASENRA (benralizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationMDI Bonanza. Dwayne Griffin, DO
MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing
More informationNancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationQuestion I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device
What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power
More informationAIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationNew and Novel Medications for Respiratory Care
New and Novel Medications for Respiratory Care JASON MOORE, PHARM.D. BCCCP CLINICAL STAFF PHARMACIST STORMONT-VAIL HEALTH Objectives Quick overview of the newest FDA-approved repiratory-related medications
More informationAsthma COPD Update 2018
Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State
More informationCOPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator
Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationTake My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care
Take My Breath Away: Update Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care Objectives 1. Recognize clinical signs and symptoms associated with chronic bronchitis and emphysema. 2. Describe
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationDrug Effectiveness Review Project Summary Report
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationAsthma & COPD Medication Review. Hutchison Disclosures 2/16/2017. Objectives
Asthma & COPD Medication Review Anna Meador, PharmD, BCACP Assistant Professor/ Pharmacy Director McWhorter School of Pharmacy/ Christ Health Center Amber Hutchison, PharmD, BCPS Assistant Clinical Professor
More informationImpact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients
Impact of a Comprehensive COPD Therapeutic Interchange Program on 30-Day Readmission Rates in Hospitalized Patients Maren A. McGurran, PharmD, BCPS; Lisa M. Richter, PharmD, BCPS, BCCCP; Nathan D. Leedahl,
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationDiagnosis and Management of Asthma
Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:
More informationMichelle Zeidler, MD, MS
7/1/18 Chronic Obstructive Pulmonary Disease: Optimizing Outpatient Care & Reducing Exacerbations Michelle Zeidler, MD, MS Professor of Medicine, Pulmonary, Critical Care Medicine & Sleep Medicine, VA
More informationUpdate on Pulmonary Diseases. Jeffrey Lessar, MD
Update on Pulmonary Diseases Jeffrey Lessar, MD 1 No disclosures to make No conflicts 2 Goals Update on key changes in Pulmonary Therapy 3 Spirometry Spirometry FEV1- forced expiratory Volume in 1 Sec
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationbenralizumab (Fasenra )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationYour Inhaler Devices & You
1 Your Inhaler Devices & You COUNSEL ON THE APPROPRIATE USE OF A: METERED DOSE INHALER (MDI) DRY POWDER INHALER (DPI) DISCUSS THE APPROPRIATE USAGE OF A PEAK FLOW METER AND SPACER/HOLDING CHAMBER DEVICE
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial
More informationS P I R O M E T R Y. Objectives. Objectives 2/5/2019
S P I R O M E T R Y Dewey Hahlbohm, PA-C, AE-C Objectives To understand the uses and importance of spirometry testing To perform spirometry testing including reversibility testing To identify normal and
More informationEffective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017
Protocol Title: Adult Asthma Protocol Effective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017 1 Purpose & Objective This protocol provides evidence-based
More informationAsthma/COPD Update with Inhaler Workshop
Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Medication Acronyms SABA: Short acting
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
More informationWhat do pulmonary function tests tell you?
Pulmonary Function Testing Michael Wert, MD Assistant Professor Clinical Department of Internal Medicine Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical
More informationA Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD
A Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD Chris Federico PharmD, BCACP RIPF Kimberly McDonough Spring Seminar May 4, 2016 Disclosure I have no actual
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationAsthma By Mayo Clinic staff
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationKey features and changes to these four components of asthma care include:
Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationAllergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma
Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationLearning Objective. Asthma. Discuss the pathophysiology, clinical presentation, diagnosis, and treatment of Asthma 2/22/2017
Marianne Curran, PA C 3/1/17 Learning Objective Discuss the pathophysiology, clinical presentation, diagnosis, and treatment of Definition many variations Chronic Disorder with Reversible (Intermittent
More informationNucala (mepolizumab injection for subcutaneous use)
Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationMedical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017
Medical Directive Pre and Post Bronchodilator Spirometry Testing and Treatment Initiation Assigned Number: Activation Date: April 24, 2013 Review due by: December 1, 2019 23 Approval Signature & Date Medical
More informationTeacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology
Title: Spirometry Teacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology I. Measurements of Ventilation Spirometry A. Pulmonary Volumes 1. The tidal
More informationcontinuing education for pharmacists
continuing education for pharmacists Volume XXXIV, No. 12 Asthma: Approaches to Treatment and New Therapies Cortney M. Mospan, PharmD, BCACP, CGP, Assistant Professor of Pharmacy, Wingate University School
More informationIncorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationChronic Obstructive Pulmonary Disease
Quality Department Guidelines for Clinical Care Ambulatory COPD Guideline Team Team Leader Davoren A Chick, MD General Medicine Team Members Paul J Grant, MD General Medicine R Van Harrison, PhD Learning
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationAsthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION
Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationAnyone who smokes and/or has shortness of breath and sputum production could have COPD
COPD DIAGNOSIS AND MANAGEMENT CHECKLIST Anyone who smokes and/or has shortness of breath and sputum production could have COPD Confirm Diagnosis Presence and history of symptoms: Shortness of breath Cough
More informationCOPD. Understanding. An educational health series from National Jewish Health IN THIS ISSUE. What is COPD? 2. How is COPD Managed?
Understanding COPD The Mount Sinai National Jewish Health Respiratory Institute was formed by the nation s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationBalanced information for better care. Helping patients with COPD breathe easier
Balanced information for better care Helping patients with COPD breathe easier COPD is the third-leading cause of death in the U.S., following cancer and heart disease 1 FIGURE 1. Women now have a higher
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationAsthma in Day to Day Practice
Asthma in Day to Day Practice VIJAY.K.VANAM Financial relationships: Disclosures Employed at Mercy Medical Center, Mason City. Nonfinancial relationships: I receive no financial gain from any pharmaceutical
More informationRespiratory Medications and Devices Update 2/15
Respiratory Medications and Devices Update 2/15 Dewey Hahlbohm, PA-C, AE-C Wendy Brown, Pharm.D., MPAS, PA-C, AE-C Objectives! Review mechanism of action for asthma pharmacologic agents! Describe key patient
More informationUpdates in the Management of Asthma and COPD. Case 1
Updates in the Management of Asthma and COPD Soraya Azari, MD Associate Clinical Professor of Medicine Case 1 40yo F with a history of asthma, allergic rhinitis, nicotine dependence, and obesity comes
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More information